Compare · RAIN vs TMO
RAIN vs TMO
Side-by-side comparison of Rain Enhancement Technologies Holdco Inc. (RAIN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- RAIN operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 9731.7x RAIN ($17.9M).
- Over the past year, RAIN is down 40.3% and TMO is up 14.9% - TMO leads by 55.2 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 1 for RAIN).
- TMO has more recent analyst coverage (25 ratings vs 8 for RAIN).
- Company
- Rain Enhancement Technologies Holdco Inc.
- Thermo Fisher Scientific Inc
- Price
- $2.15-0.46%
- $469.56-0.67%
- Market cap
- $17.9M
- $174.52B
- 1M return
- +13.46%
- -1.03%
- 1Y return
- -40.28%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 17
- Recent ratings
- 8
- 25
Rain Enhancement Technologies Holdco Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest RAIN
- Chief Executive Officer Seidl Randy bought $100,949 worth of shares (42,514 units at $2.37), increasing direct ownership by 7% to 644,834 units (SEC Form 4)
- SEC Form 10-Q filed by Rain Enhancement Technologies Holdco Inc.
- SEC Form SCHEDULE 13G filed by Rain Enhancement Technologies Holdco Inc.
- One Additional Inch of Rainfall from Ground-Based Rain Enhancement Worth $44 Million Annually to 37 Texas Counties, Texas A&M Analysis Finds
- SEC Form EFFECT filed by Rain Enhancement Technologies Holdco Inc.
- SEC Form 424B3 filed by Rain Enhancement Technologies Holdco Inc.
- SEC Form POS AM filed by Rain Enhancement Technologies Holdco Inc.
- Rain Enhancement Technologies Introduces Industry-First Guaranteed 10% Precipitation Enhancement
- SEC Form 10-K filed by Rain Enhancement Technologies Holdco Inc.
- SEC Form 424B3 filed by Rain Enhancement Technologies Holdco Inc.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)